Therefore, blocking MDM2-mediated TOP2β degradation by RG7112 synergistically suppresses lung cancer cell survival following treatment with VP-16, resulting in an increase in apoptosis and susceptibility to VP-16 treatment. This evidence concerns the gene MDM2 and lung cancer.